Mother-to-child transmission of hepatitis B virus (HBV) accounts for the majority of cases of chronic HBV infection. HBV infection affects more than 250 million people worldwide and in many cases results in cirrhosis or hepatocellular carcinoma. As such, there has been interest in preventing perinatal transmission.
The most recent study (C Jourdain et al. NEJM 2018; 378: 911-23) again showed that tenofovir administration to pregnant women with HBV can prevent transmission. This study enrolled 331 women. Key findings:
- 0% (0/147) infants in the tenofovir group developed HBV infection compared to 2% (3/147) in the control group. This did not reach statistical significance
- The placebo group received HBV vaccination and hepatitis B immune globulin 1.2 hours and 1.3 hours after birth (median time). This rapid provision of treatment along with completion of four doses of HBV vaccine likely helped keep the placebo group HBV infection rate low
In the related editorial (G Dusheiko. pg 952-3), it is noted that “current levels of evidence supporting antiviral therapy with TDF [tenofovir] (or possbily lamivudine or telbivudine) to reduce levels of maternal HBV DNA during pregnancy have been accepted by the” AASLD.
Related blog posts:
- Preventing Neonatal Hepatitis B Transmission with Tenofovir | gutsandgrowth
- Preventing Vertical Transmission of Hepatitis B with Telbivudine | gutsandgrowth
- Predicting Hepatitis B Vaccination Failure in Infants
- Antivirals Reduce Vertical Transmission of Hepatitis B
- More on perinatal HBV
- Burden of Hepatitis B and Hepatitis C | gutsandgrowth
- How to stop HBV vertical transmission | gutsandgrowth